Q1 EPS Forecast for Gain Therapeutics Boosted by Analyst

Gain Therapeutics, Inc. (NASDAQ:GANX) – Analysts at HC Wainwright raised their Q1 2026 EPS estimates for shares of Gain Therapeutics in a research note issued to investors on Monday, March 30th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.13) per share for the quarter, up from their previous forecast of ($0.15). HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for Gain Therapeutics’ Q2 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.50) EPS, Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.13) EPS, Q4 2027 earnings at ($0.11) EPS and FY2027 earnings at ($0.47) EPS.

Gain Therapeutics (NASDAQ:GANX) last posted its earnings results on Thursday, March 26th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03.

A number of other equities research analysts have also weighed in on GANX. Roth Mkm restated a “buy” rating and set a $10.00 price objective on shares of Gain Therapeutics in a research report on Friday, December 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Gain Therapeutics in a research report on Monday, December 29th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $8.50.

Gain Therapeutics Price Performance

Shares of GANX opened at $1.94 on Wednesday. Gain Therapeutics has a 52 week low of $1.41 and a 52 week high of $4.34. The stock has a market capitalization of $81.95 million, a price-to-earnings ratio of -3.18 and a beta of 0.11. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.63 and a current ratio of 6.63. The stock has a fifty day moving average of $2.13 and a 200-day moving average of $2.37.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP increased its stake in shares of Gain Therapeutics by 849.3% in the fourth quarter. Marshall Wace LLP now owns 1,662,293 shares of the company’s stock valued at $5,353,000 after buying an additional 1,487,186 shares during the period. Potomac Capital Management Inc. acquired a new stake in Gain Therapeutics during the 4th quarter valued at approximately $3,252,000. Jane Street Group LLC raised its holdings in Gain Therapeutics by 234.5% during the 4th quarter. Jane Street Group LLC now owns 242,328 shares of the company’s stock worth $780,000 after purchasing an additional 169,878 shares during the last quarter. LPL Financial LLC acquired a new position in shares of Gain Therapeutics in the 4th quarter worth approximately $343,000. Finally, State Street Corp boosted its stake in shares of Gain Therapeutics by 72.9% in the 4th quarter. State Street Corp now owns 157,537 shares of the company’s stock valued at $507,000 after purchasing an additional 66,400 shares during the last quarter. 11.97% of the stock is owned by institutional investors and hedge funds.

Gain Therapeutics News Roundup

Here are the key news stories impacting Gain Therapeutics this week:

• Positive Sentiment: HC Wainwright raised several near‑term EPS forecasts (Q1–Q2 2026, Q4 2026) and trimmed losses for FY2026 (from ($0.55) to ($0.50)) and set FY2027 at ($0.47); the firm kept a Buy rating and an $8 target — a clear positive signal from a sell‑side analyst that could support upside interest. MarketBeat: Gain Therapeutics Analyst Updates
• Neutral Sentiment: HC Wainwright’s updated quarterly estimates are still negative (quarterly EPS forecasts generally range ~$-0.11 to -0.13), reflecting continued operating losses — the revisions improve visibility but do not indicate near‑term profitability. MarketBeat: Gain Therapeutics Analyst Updates
• Negative Sentiment: Despite estimate improvements and a bullish $8 target, the company remains unprofitable with a consensus full‑year EPS around ($1.00); absent clinical or commercial catalysts in the notes, the path to sustained stock gains may be limited and dependent on future R&D progress or financing. MarketBeat: Gain Therapeutics Analyst Updates

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.